ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 239,99
0,17%
Dow Jones
39 908,00
0,88%
DAX
18 869,36
0,78%
Brent Oil
82,705
0,19%
Bitcoin
65 986,78
7,23%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) Actualités

CNTA Centessa Pharmaceuticals PLC

8,815
-0,225 (-2,49%)
Après les heures de négociation
Dernière mise à jour : 22:01:03
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Centessa Pharmaceuticals PLC CNTA NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,225 -2,49% 8,815 22:01:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
9,04 8,70 9,33 8,815 9,04
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
13/5/202422:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202422:23EDGAR2Form 8-K - Current report
13/5/202422:10GLOBECentessa Pharmaceuticals Reports Financial Results and..
09/5/202414:01EDGAR2Form ARS - Annual Report to Security Holders
09/5/202414:00EDGAR2Form DEF 14A - Other definitive proxy statements
24/4/202403:36GLOBECentessa Pharmaceuticals Announces Pricing of $100 Million..
23/4/202422:17GLOBECentessa Pharmaceuticals Announces $100 Million Proposed..
22/4/202413:00GLOBECentessa Pharmaceuticals Announces Open IND for ORX750;..
28/3/202421:28GLOBECentessa Pharmaceuticals Reports Business Highlights and..
22/2/202414:00GLOBECentessa Pharmaceuticals to Participate in TD Cowen’s 44th..
09/2/202413:12EDGAR2Form 8-K - Current report
09/2/202413:00GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
02/2/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:07EDGAR2Form 144 - Report of proposed sale of securities
22/1/202414:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
09/1/202413:56EDGAR2Form 8-K - Current report
03/1/202401:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202314:00GLOBECentessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P...
11/12/202313:05EDGAR2Form 8-K - Current report
10/12/202318:05GLOBECentessa Pharmaceuticals Announces New Data from an..
27/11/202322:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
13/11/202322:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:17EDGAR2Form 8-K - Current report
13/11/202322:05GLOBECentessa Pharmaceuticals Reports Financial Results and..
02/11/202314:09GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
31/10/202313:00GLOBECentessa Pharmaceuticals Announces Dosing of First Subject..
30/10/202313:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
25/10/202315:49EDGAR2Form 8-K - Current report
25/10/202314:00GLOBECentessa Pharmaceuticals Announces Preclinical Data..
03/10/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202314:00GLOBECentessa Pharmaceuticals Announces Additions to Senior..
22/9/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202322:02EDGAR2Form 144 - Report of proposed sale of securities
01/9/202322:31EDGAR2Form 144 - Report of proposed sale of securities
31/8/202314:00GLOBECentessa Pharmaceuticals to Participate in the Morgan..
23/8/202323:08GLOBECentessa Pharmaceuticals to Present Preclinical Data for..
14/8/202313:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202313:06EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
CNTA
Centessa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés